MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- IPCA LABORATORIES LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
IPCA Labs Quarterly Results 
(IPLB)
Here are the latest quarterly results of IPCA Labs. For more details, see the IPCA Labs financial fact sheet and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.
IPCA Labs Quarterly Results
| No. of Mths Qtr. Ending |
3
Dec-16 |
3
Mar-17* |
3
Jun-17 |
3
Sep-17 |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 7,507 | 6,658 | 7,130 | 8,643 | 8,592 | 7,828 | 8,539 | 9,978 | |
| Other income | Rs m | 59 | 52 | 62 | 110 | 110 | 114 | 136 | 138 | |
| Turnover | Rs m | 7,567 | 6,710 | 7,191 | 8,753 | 8,702 | 7,941 | 8,676 | 10,116 | |
| Expenses | Rs m | 6,443 | 5,981 | 6,914 | 7,153 | 6,980 | 6,729 | 7,399 | 8,250 | |
| Gross profit | Rs m | 1,065 | 677 | 215 | 1,490 | 1,612 | 1,099 | 1,140 | 1,728 | |
| Depreciation | Rs m | 432 | 428 | 433 | 441 | 438 | 432 | 445 | 432 | |
| Interest | Rs m | 57 | 44 | 56 | 64 | 56 | 65 | 49 | 24 | |
| Profit before tax | Rs m | 636 | 257 | -212 | 1,096 | 1,228 | 717 | 782 | 1,410 | |
| Tax | Rs m | 222 | -187 | -10 | 131 | 172 | 204 | 127 | 213 | |
| Profit after tax | Rs m | 414 | 444 | -203 | 965 | 1,056 | 513 | 655 | 1,197 | |
| Gross profit margin | % | 14.2 | 10.2 | 3.0 | 17.2 | 18.8 | 14.0 | 13.4 | 17.3 | |
| Effective tax rate | % | 34.9 | -72.7 | 4.6 | 12.0 | 14.0 | 28.4 | 16.2 | 15.1 | |
| Net profit margin | % | 5.5 | 6.7 | -2.8 | 11.2 | 12.3 | 6.6 | 7.7 | 12.0 | |
| Diluted EPS | Rs | 3.3 | 3.5 | -1.6 | 7.6 | 8.4 | 4.1 | 5.2 | 9.5 | |
| Diluted EPS (TTM) | Rs | 11.9 | 14.9 | 9.5 | 12.8 | 17.9 | 18.5 | 25.3 | 27.1 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: IPCA Labs 2QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: FULFORD INDIA DR. REDDYS LAB ALKEM LABORATORIES J.B.CHEMICALS ELDER PHARMA
Compare IPCA LABS With: FULFORD INDIA DR. REDDYS LAB ALKEM LABORATORIES J.B.CHEMICALS ELDER PHARMA
Compare IPCA LABS With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends Flat; IT & Energy Stocks Gain(Closing)
Indian share markets traded on a volatile note throughout the day and ended their session on a flat note. Sectoral indices ended on a mixed note with stocks in the IT sector.
Views on news
IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)
Nov 15, 2018 | Updated on Nov 15, 2018For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)
Aug 13, 2018 | Updated on Aug 13, 2018For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)
Jan 9, 2019For the first time, we have recommended a bluechip stock in Smart Money Secrets.
3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)
Jan 11, 2019The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling
Follow a Super Investor Like This to Multiply Your Wealth(The 5 Minute Wrapup)
Jan 4, 2019Following a super investor can certainly help build a portfolio and create wealth in the long term.
15 Mistakes to Avoid to Make a Killing in the Markets(Profit Hunter)
Jan 3, 2019Richa dissects the common mistakes investors make and how to avoid and even take advantage of them.
My First Stock Trading Recommendation For 2019(Profit Hunter)
Jan 10, 2019My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.
More|
| |
IPCA LABS SHARE PRICE
Jan 16, 2019 (Close)
TRACK IPCA LABS
- Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON IPCA LABS
IPCA LABS 5-YR ANALYSIS
COMPARE IPCA LABS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited(Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.